Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

FDA Approves TriClip TEER Device for Tricuspid Repair

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

Top Endovascular News of 2023

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

TCTMD’s Top 10 Most Popular Stories for January 2019

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content